Minutes from the Extraordinary General Meeting
Oslo, Norway, November 20, 2023 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held an Extraordinary General Meeting today, November 20th, at 13:00 hours (CET) on the Company’s premises in…
Presentation of GA-map® by Genetic Analysis sparks great interest at xMAP® Connect EMEA in Amsterdam
Genetic Analysis recently participated in xMAP® Connect EMEA, an industry conference November 8-9 in Amsterdam organized by Luminex Corporation – a DiaSorin Company. Here, GA presented the latest news about…
Notice of Extraordinary General Meeting 2023
Notice is hereby served that an extraordinary general meeting in Genetic Analysis AS (the “Company”) will be held on Monday 20 November2023 at 13:00 hours in the Company’s premises in…
Information avseende nyttjandeperiod av teckningsoptioner av serie TO 2 i Genetic Analysis AS
OSLO, NORGE – 3 november, 2023 – Den 8 november 2023 inleds nyttjandeperioden för de teckningsoptioner av serie TO 2 som emitterades i samband med Genetic Analysis AS:s (“GA” eller…
Correction: Updated intended record date for the intended Subsequent Offering announced in press release, November 2, 2023
Correction of press release regarding subsequent offer
Subscriptions received in separate tranche of previously announced directed share issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA,…
Board member resigns at his request
OSLO, NORWAY – November 2, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the board member Staffan Strömberg has resigned from the Board of…
Genetic Analysis: Launch of GA-map® Discovery – A microbiome profiling offering for Research Customers
GA-map new product Discovery launch
Genetic Analysis: Development project initiated for a new companion diagnostic test
OSLO, NORWAY – 12 October 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed a pilot project and initiated a development…
Half-year report January–June 2023
OSLO, NORWAY, August 30, 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the half-year report for the second quarter and first six months of 2023. The half-year…
Genetic Analysis AS ramps up its market presence for the GA-map® microbiome testing in the US
OSLO, NORWAY – August 25, 2023: Microbiome diagnostics specialist, Genetic Analysis AS (“GA”) has through its distributor Eagle Biosciences Inc, entered an agreement with an undisclosed partner, a high-volume lab…
New publication shows the benefits of the GA-map® testing platform in Diabetes Type 2
OSLO, NORWAY – 23 August 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that a scientific article has recently been published in the medical journal BMC…
Genetic Analysis receives patent approval in South Africa
OSLO, NORWAY – June 29, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded a patent (2017/06307) by the South African…